HLA-B*44 is associated with a more than twentyfold increase in cyclic citrullinated peptide antibody serum level in Croatian patients with seropositive rheumatoid arthritis
PLOS One · 2025
DOI: 10.1371/journal.pone.0334551 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Jure Aljinović und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Physical Medicine and Rehabilitation with Rheumatology, University Hospital of Split, Split, Croatia. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Peptides, Cyclic, Anti-Citrullinated Protein Antibodies, HLA-B Antigens. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To determine whether any of the HLA-A*, HLA-B* and HLA-DR* alleles in seropositive rheumatoid arthritis (RA) can be associated with the extreme serum levels of rheumatoid factor (RF) and cyclic citrullinated peptide antibodies (anti-CCP).
Methods
This was a retrospective cross-sectional study of adult patients. Demographic data, HLA typing data and RF and anti-CCP levels were collected and analysed.
Results
HLA-A*02, HLA-B*44 and HLA-DRB1*04 were more prevalent in patients from the RA cohort compared to healthy controls. Intra-cohort analysis revealed that HLA-B*44 had an increased frequency of a twenty-fold increase in anti-CCP (P = 0.033) and HLA-A*03 had a borderline (P = 0.063) frequency. HLA-A*03 was more frequent in the groups with >3-fold and >10-fold anti-CCP levels, while HLA-DRB1*04 was of borderline significance at >3-fold anti-CCP increase (P = 0.053). HLA-B*08 showed a lower frequency of 3-, 10- and 20-fold increase in anti-CCP serum levels. Carriers of B*44 (OR = 5.58; P = 0.030), DRB1*04 (OR = 3.89; P = 0.027) or A*03 (OR = 2.71; P = 0.023) were statistically significantly more likely to have a 20-fold increase in anti-CCP levels over the diagnostic threshold. None of the alleles increased the likelihood of having high or extreme RF levels.
Conclusions
HLA-B*44 is associated with a twenty-fold increase in anti-CCP serum levels. HLA-A*03 and HLA-DRB1*04 have a positive trend towards a twenty-fold increase in anti-CCP levels. Earlier aggressive therapy in these patients can prevent such an extreme increase in antibody levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Physical Medicine and Rehabilitation with Rheumatology, University Hospital of Split, Split, Croatia.
- University of Split School of Medicine, Split, Croatia.
- Faculty of Health Sciences, University of Split, Split, Croatia.
- Study Program of Dental Medicine, University of Split School of Medicine, Croatia.
- Department of Internal Medicine, Division of Rheumatology, Allergology and Clinical Immunology, University Hospital of Split, Croatia.
- Division of Transfusion Medicine, University Hospital of Split, Croatia.
ORCID-Profile: Jure Aljinović, Darko Kero
Zitieren
APA
Aljinović, J., Kero, D., Šošo, D., Petrić, M., Marasović Krstulović, D., Perković, D., Čečuk-Jeličić, E., Jaman, S., Dujmović, D., & Marinović, I. (2025). HLA-B*44 is associated with a more than twentyfold increase in cyclic citrullinated peptide antibody serum level in Croatian patients with seropositive rheumatoid arthritis. PLOS One. https://doi.org/10.1371/journal.pone.0334551
Vancouver
Aljinović J, Kero D, Šošo D, Petrić M, Marasović Krstulović D, Perković D, et al. HLA-B*44 is associated with a more than twentyfold increase in cyclic citrullinated peptide antibody serum level in Croatian patients with seropositive rheumatoid arthritis. PLOS One. 2025. doi:10.1371/journal.pone.0334551
BibTeX
@article{Aljinovi2025,
author = {Aljinović, Jure and Kero, Darko and Šošo, Daniela and Petrić, Marin and Marasović Krstulović, Daniela and Perković, Dijana and Čečuk-Jeličić, Esma and Jaman, Sonja and Dujmović, Dora and Marinović, Ivanka},
title = {HLA-B*44 is associated with a more than twentyfold increase in cyclic citrullinated peptide antibody serum level in Croatian patients with seropositive rheumatoid arthritis},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0334551}
}
EUVIMED